Neurofibromatosis $ 5 donation.
A team of UAB geneticists, doctors and biostatisticians has received $ 5.7 million Department of Defense to study and test new treatments for neurofibromatosis, or NF. UAB is the main research center in a newly established group called the NF Consortium. The coalition consists of more than two years to design and manage multiple clinical trials in the nation for new and more effective treatment options for adults and children with a diagnosis of NF. The award of $ 5.7 million will be shared among members of the NF Consortium, the research team UABs that acts as a hub and distribution point for government funds.Bruce Korf, MD, Ph.D., chairman of the UAB Department of Genetics and an internationally recognized expert in neurofibromatosis type 1, said the consortiums goal is
to simplify and improve the way the experiments are carried clinical disease, and break the barriers of the past to discover and test cutting-edge treatments NF. We await the results of studies of the NF Consortium to provide a wide range of treatment options for patients in order to reduce the rate of tumor growth, and improve the quality of life, Korf said.By monitoring not only clinical outcomes, but the effects of therapies against molecular targets will be possible to better understand NF as a disease, he said. The other eight participating institutions include Childrens Hospital Boston, Childrens Hospital of Philadelphia, Childrens National Medical Center in Washington, DC, Cincinnati Childrens Hospital Medical Center, Washington University in St. Louis, the
University of Chicago, University of Utah in Salt Lake City, and the National Cancer Institute in Bethesda, Md.Often diagnosed in childhood, NF is a genetic disease, the tumors on nerve tissue that affects many body systems are growing causes. As tumors grow, they can press the key areas and lead to birth defects, high blood pressure, scoliosis, speech problems, premature or delayed puberty, blindness and other medical
Pages: [1] 2